EVER/TMC Mutation as Marker of the Risk of Cutaneous Carcinoma in Immunosuppressed Patients (EBVER/TMC)

Andreas Arnold

Status: Completed

Conditions: Neoplasm; Immunosuppression

Study type: Observational

Funder types: Other

Identifiers

NCT01942005

11/10

Details and patient eligibility

About

Detection of mutation / specific polymorphism of the EVER/TMC6 and/or EVER/TMC8 gen.

Full description

correlation between possibly detected mutation/specific polymorphism and kind and number of neoplasm, age of patients, UV burden, duration and kind of immunosuppression.

Enrollment: 144 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients in an immunosuppressive condition either by immunosuppressants or by HIV infection

Exclusion criteria

• written informed consent not given